Co-Authors
This is a "connection" page, showing publications co-authored by AHMED KASEB and BRUNO CALAZANS ODISIO.
Connection Strength
1.880
-
Anti-angiogenic therapy in the setting of TACE: an elusive synergy? Lancet Gastroenterol Hepatol. 2018 01; 3(1):5-6.
Score: 0.610
-
Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg. 2023 09; 27(9):1867-1875.
Score: 0.226
-
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1129-1145.
Score: 0.200
-
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
Score: 0.150
-
Minimally invasive image-guided therapies for hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 3:55-61.
Score: 0.143
-
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 3:1-7.
Score: 0.136
-
Transarterial hepatic chemoembolization with 70-150 ?m drug-eluting beads: assessment of clinical safety and liver toxicity profile. J Vasc Interv Radiol. 2015 Jul; 26(7):965-71.
Score: 0.130
-
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. medRxiv. 2024 Sep 12.
Score: 0.062
-
Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol. 2021 Dec 21; 27(47):8166-8181.
Score: 0.051
-
Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma. 2020; 7:117-131.
Score: 0.047
-
Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2020 Feb; 43(2):311-321.
Score: 0.044
-
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019 04; 133:54-61.
Score: 0.042
-
Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma. J Clin Med. 2018 Apr 14; 7(4).
Score: 0.040